Ergocalciferol

Quick links to important sections

Ergocalciferol

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ergocalciferol

What is Ergocalciferol?

Ergocalciferol, also known as vitamin D2, is a fat-soluble vitamin that plays a significant role in maintaining the body’s mineral balance. It is one of the two primary forms of vitamin D available to humans, the other being cholecalciferol (vitamin D3). While vitamin D3 is synthesized by the skin through exposure to ultraviolet B (UVB) light, ergocalciferol is derived primarily from plant-based sources and fungi, such as yeast and mushrooms, that have been exposed to UV light.

Mechanism and Biological Role

Once ingested, ergocalciferol undergoes a two-step activation process within the body. It is first converted in the liver and subsequently in the kidneys into its biologically active hormone form. This active form is essential for several physiological processes, most notably the regulation of calcium and phosphorus levels.

The primary functions of this vitamin include:

  • Intestinal Absorption: Facilitating the absorption of calcium and phosphorus from the diet through the intestinal tract.
  • Bone Health: Supporting the mineralization and maintenance of bone structure by ensuring adequate levels of circulating calcium.
  • Renal Function: Assisting the kidneys in reabsorbing calcium that would otherwise be excreted in the urine.

Clinical Applications

Ergocalciferol is utilized in clinical settings to address conditions characterized by vitamin D deficiency or impaired calcium metabolism. Because it helps maintain skeletal integrity, it is often used in the management of metabolic bone disorders. It is also an important option for individuals who require vitamin D supplementation but prefer a plant-derived or non-animal source.

Regulatory References

  1. MedlinePlus (NIH/NLM)

What side effects are possible with Ergocalciferol?

Possible side effects and safety information

The safety profile of Ergocalciferol (Vitamin D2) is primarily defined by the risks associated with Hypervitaminosis D and resulting Hypercalcemia (excessive calcium in the blood), which represents the core adverse consequence of the medicine's systemic effect. Documented adverse reactions are generally manifestations of this toxicity.

Adverse Reaction Categories and Systems

Adverse reactions are officially classified by the physiological systems they affect. Effects are documented across the Gastrointestinal system (e.g., nausea, anorexia, constipation), the Renal system (e.g., polyuria, hypercalciuria), and the Metabolism and Nutrition system (e.g., weight loss, mild acidosis). In some regulatory contexts, reactions such as rash and pruritus have been classified as Rare.

Serious Adverse Reactions

Severe, uncorrected hypercalcemia can lead to serious adverse reactions explicitly documented in regulatory labeling. These include Irreversible renal insufficiency, which may result in fatal outcomes, and Widespread calcification of soft tissues, involving structures such as blood vessels, the heart, and the lungs. Additionally, Generalized vascular calcification is a documented risk.

Population and Duration-Related Safety Notes

The medicine is contraindicated (prohibited) for use in individuals with pre-existing conditions such as Hypercalcemia or Hypervitaminosis D. Specific safety considerations apply to pediatrics, where excessive exposure has been associated with a decline in the rate of linear growth. Furthermore, the effects of Ergocalciferol on the body can officially persist for two or more months after treatment is discontinued.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from Ergocalciferol is officially documented as Hypervitaminosis D, a physiological state primarily defined by persistent and dangerous elevations in blood calcium, known as hypercalcemia. Officially documented manifestations of overdose often present with gastrointestinal symptoms, including nausea, vomiting, abdominal pain, and constipation. Other signs listed in regulatory sources are headache, weakness, polyuria (increased urination), and polydipsia (increased thirst).

Severe or chronic hypercalcemia can lead to serious and life-threatening complications. Regulatory documents state that these outcomes include renal failure (which may be reversible or irreversible), nephrocalcinosis, and documented cardiovascular effects such as cardiac arrhythmias. The mandated first action for a suspected overdose is the immediate cessation of the medicine's administration.

Patients must seek immediate medical attention or contact emergency services if severe or life-threatening symptoms—such as persistent vomiting, signs of kidney distress, or cardiac abnormalities—are present. Official labeling states that no specific antidote is known; therefore, treatment is limited to regulator-described symptomatic and supportive measures, including potential hospital monitoring and the provision of a low-calcium diet.

Therapeutic Uses of Ergocalciferol

What Ergocalciferol Treats: Main Uses and Benefits

Ergocalciferol, or Vitamin D2, is commonly used to help with conditions where functional stability becomes affected due to symptoms related to systemic imbalance of calcium and phosphate. The medication may be part of symptomatic management in the therapeutic domain of hypoparathyroidism, as well as in addressing refractory rickets (vitamin D-resistant rickets) and familial hypophosphatemia.

These are conditions characterized by periods of heightened symptoms related to bone and mineral health. This therapeutic domain is relevant when supportive symptom management is appropriate for symptoms of systemic imbalance. It is applied in addressing conditions marked by temporary physiological imbalance, which contributes to improved comfort during periods of heightened symptoms. It may assist with maintaining the balance needed and provides supportive relief when symptoms interfere with routine activities associated with these conditions.

“It helps improve day-to-day comfort during symptomatic periods and supports patients during episodes of heightened discomfort.”

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Regulatory References

  1. FDA-Sourced Drug Label for Ergocalciferol

Eligibility and Restrictions for Use

Who Can and Cannot Use Ergocalciferol

Official regulatory documents define strict population-based eligibility rules for using Ergocalciferol (Vitamin D2).

Contraindicated Populations

Use of Ergocalciferol is contraindicated in patients with pre-existing conditions that relate to toxicity or absorption, specifically Hypercalcemia (high blood calcium levels), Hypervitaminosis D (excessive Vitamin D levels), Malabsorption Syndrome, and documented Abnormal Sensitivity to the toxic effects of Vitamin D. Some regional labels also list patients with severe renal impairment and Nephrolithiasis (kidney stones) as contraindicated.


Restricted and Special Populations

Population Group Regulatory Status
Pediatric Patients Doses must be individualized; use is strictly restricted in infants with Idiopathic Hypercalcemia.
Pregnant Women Safety is not established for doses exceeding 400 USP units daily; use should be avoided unless benefits outweigh hazards (Category C).
Nursing Women Caution should be exercised; monitoring of the infant’s calcium levels is required when the mother receives large doses.
Geriatric Patients Clinical studies did not include sufficient numbers to determine if they respond differently.
Renal Function Impairment Requires particular caution and frequent monitoring.
Sarcoidosis Use requires caution due to the increased conversion risk to the active metabolite.

These classifications detail who is eligible for treatment for indicated conditions such as Hypoparathyroidism, and who must be excluded from use based on official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes several interaction patterns for Ergocalciferol, primarily concerning its effects on calcium balance and its own absorption and metabolism.

Documented Interaction Classifications

The co-administration of Ergocalciferol with other high-dose Vitamin D analogues or supplements is restricted due to the formal risk of Hypervitaminosis D (vitamin D toxicity).

Interacting Agent Class Officially Documented Interaction Pattern
Pharmacodynamic Agents (Thiazide Diuretics, Cardiac Glycosides) Increased risk of hypercalcemia and related cardiac toxicity (e.g., arrhythmias) due to an additive effect on serum calcium levels.
Pharmacokinetic Agents (CYP Inducers/Anticonvulsants) Agents like phenytoin can increase the metabolic clearance of Ergocalciferol, officially resulting in a decreased pharmacologic effect.
Absorption Impairment (Bile Acid Sequestrants, Mineral Oil) These substances impair the intestinal absorption of the fat-soluble Ergocalciferol, leading to a reduced serum concentration of the medicine.

Administration Constraints

Mandatory constraints define that the oral administration of Ergocalciferol must be separated by several hours from substances like mineral oil to prevent diminished absorption. The risk of hypercalcemia when using thiazide diuretics is specifically highlighted in official labeling for hypoparathyroid patients.

Mechanism of Action

Ergocalciferol's mechanism of action is executed entirely by its active metabolite, which fundamentally regulates mineral homeostasis by functioning as a ligand-activated transcription factor.


Genomic Activation of the Vitamin D Receptor ( VDR)

The primary action begins with the active metabolite acting as a full agonist at the Vitamin D Receptor ( VDR), a nuclear receptor. This agonism modulates the transcription of key genes (via binding to VDREs) responsible for mineral transport in the small intestine and the kidney. This genomic mechanism is essential for increasing the active uptake of dietary calcium ( Ca^2+) and phosphate across the gastrointestinal tract, contributing to the systemic mineral availability.


Regulation of the Parathyroid-Renal Axis

The mechanism also involves a critical endocrine feedback loop. VDR activation directly suppresses the synthesis and release of Parathyroid Hormone ( PTH), a major regulator of blood calcium. Concurrently, the drug enhances the expression of transport proteins in the kidney, which significantly increases the reabsorption of filtered Ca^2+. This dual action conserves the body's existing mineral pool and minimizes systemic calcium loss, supporting the stabilization of normocalcemia (stable blood mineral concentration). This stabilization provides the mineral concentrations required for bone matrix deposition.


Mechanistic Constraints Due to Metabolic Dependence

The drug's effectiveness is constrained by its reliance on 1 -alpha-hydroxylation in the kidneys to produce the final active molecule. This metabolic step establishes the required speed of activation for the mechanism. Should renal function be severely compromised, the production of the VDR agonist is significantly reduced, creating a functional limitation in the ensuing mineral homeostasis modulation.

Dosage and Administration Information

Ergocalciferol (Vitamin D2) is a prescription and over-the-counter medication used to treat conditions such as hypoparathyroidism and refractory rickets. It may also be prescribed as a dietary supplement for individuals with vitamin D deficiency.

General Administration

  • Dosage: Take this medication exactly as prescribed by your healthcare provider. The dosage is highly individualized and is based on your medical condition and the monitoring of your blood calcium and vitamin D levels. The therapeutic range is narrow, meaning too little may be ineffective and too much can be toxic.
  • Timing: Ergocalciferol is typically taken once daily. It may be best absorbed when taken with food or a meal that contains fat, as it is a fat-soluble vitamin.
  • Liquid Forms: If using the oral liquid solution, carefully measure the dose using the measuring device provided. Do not use a household spoon.

Important Considerations

  • Calcium Intake: Ergocalciferol's effectiveness depends on getting the correct amount of calcium in your diet. Your doctor may recommend specific dietary instructions or a calcium supplement. You must follow these instructions closely to prevent serious side effects.
  • Missed Dose: If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
  • Monitoring: Regular blood tests are essential while taking ergocalciferol to monitor serum calcium and vitamin D levels and allow your doctor to adjust the dose safely. Report any signs of overdose, such as weakness, nausea, or vomiting, to your healthcare provider immediately. Avoid taking other vitamin D-containing supplements unless instructed by your doctor.

Recent Clinical Evidence

Ergocalciferol, known as Vitamin D2, is primarily indicated for addressing states of Vitamin D deficiency and related conditions like hypoparathyroidism, rickets, and familial hypophosphatemia. Clinical research continues to evaluate its specific effects, particularly in comparison to cholecalciferol (Vitamin D3) and in populations with specialized health needs.


Efficacy in Vitamin D Status

Ergocalciferol administration has been consistently shown to raise serum levels of 25-hydroxyvitamin D [25(OH)D], the major circulating form of Vitamin D, in individuals with low baseline levels. However, systematic reviews and meta-analyses comparing D2 and D3 have reported that supplementation with Vitamin D3 is more efficacious in raising total 25(OH)D concentrations than D2, particularly when administered in high, intermittent doses. This finding suggests potential differences in their metabolism or clearance rates.


Specialized Population Studies

Recent randomized controlled trials (RCTs) have focused on specific clinical contexts:

  • Chronic Kidney Disease (CKD): In patients undergoing hemodialysis who had low 25(OH)D levels, ergocalciferol supplementation was shown to increase their Vitamin D status. However, studies did not consistently find a significant effect on secondary outcomes such as epoetin (ESA) utilization, parathyroid hormone, or clinical events like hospitalization rates over a six-month period.
  • Type 1 Diabetes (T1D): Research in youths newly diagnosed with T1D has explored the use of ergocalciferol as an adjunctive treatment. Findings suggest it may be associated with a statistically significant reduction in certain inflammatory markers and may influence the temporal trends of clinical markers such as Glycated Hemoglobin (HbA1c) and Insulin Dose-Adjusted A1c (IDAA1c) over 12 months, though the effect on primary markers of residual beta-cell function has been mixed.

Mineral and Hormonal Effects

A recent systematic review of RCTs indicated that Vitamin D2 supplementation may significantly decrease serum Parathyroid Hormone (PTH) concentrations and increase serum calcium levels. The effect on phosphorus concentrations has been reported as non-significant.

Key Studies & References

  1. Vitamin D supplementation for the prevention and treatment of human diseases: an umbrella review of the evidence

Frequently Asked Questions (FAQ)

Common questions about Ergocalciferol (FAQ)

Q: Is Ergocalciferol the same as Vitamin D?

Ergocalciferol is a form of vitamin D, specifically designated as Vitamin D2 (D2). Vitamin D is a group of compounds, and D2 is one of the types used as a medicine or supplement to help regulate calcium and phosphate levels in the body.


Q: What is the main difference between Ergocalciferol and Cholecalciferol?

The difference highlighted in official research relates to effectiveness. Studies comparing the two have reported that supplementation with Cholecalciferol (Vitamin D3) is generally reported to be more efficacious than Ergocalciferol (D2) at raising total 25-hydroxyvitamin D concentrations in the blood.


Q: What is the source of Ergocalciferol (plant or animal)?

Ergocalciferol is derived from the compound ergosterol, which is found in plant and fungal sources. This means Ergocalciferol is considered a non-animal-derived form of Vitamin D.


Q: Do I need a prescription to get Ergocalciferol?

Official information indicates that Ergocalciferol is available as both a prescription medicine and an over-the-counter (OTC) product. The requirement for a prescription usually depends on the specific dosage strength and the regulations of your region.


Q: Is Ergocalciferol considered a steroid?

Ergocalciferol is officially classified as a secosteroid analogue and a vitamin. While it is structurally similar to certain steroids, it has a defining characteristic (an open-ring structure) that differentiates it from classic steroid hormones.


Q: How quickly can I expect Ergocalciferol to begin working?

According to regulatory documents, there is a delay, often cited as 10 to 24 hours, between administration and the onset of its effect. This delay is due to the necessary metabolic steps that occur in the liver and kidneys to activate the medicine.


Q: How long does the effect of Ergocalciferol last in the body?

Because the medicine is fat-soluble, its effects can be long-lasting. Official adverse reaction information states that the effects of Ergocalciferol can persist for two or more months after treatment is stopped.


Q: Can Ergocalciferol cause fatigue or tiredness?

Yes, regulatory documents list unusual tiredness or weakness among the potential effects that may occur. These effects have been noted in the context of excessive vitamin D levels, or hypervitaminosis D.


Q: Are there any long-term safety concerns associated with Ergocalciferol use?

The main long-term concern described in official labeling is the risk of severe hypercalcemia (excessive calcium in the blood). Uncorrected hypercalcemia can lead to serious adverse reactions, including irreversible renal insufficiency (kidney damage) and widespread calcification of soft tissues.


Q: What happens if a dose of Ergocalciferol is taken too close to the next scheduled dose?

Official guidance for managing a missed dose states that if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Patients are cautioned not to take a double dose to compensate, which helps maintain safe blood levels.


Q: Can Ergocalciferol interact with seizure or anti-convulsant medications?

Yes, official drug interaction documents note that some anticonvulsant agents, such as phenytoin, can increase the metabolic clearance of Ergocalciferol. This process is officially described as resulting in a decreased effect of the Ergocalciferol.


Q: Can people with heart conditions safely use Ergocalciferol?

Official interaction information notes that co-administration with certain heart medicines, specifically cardiac glycosides, increases the risk of high blood calcium (hypercalcemia). The risk of hypercalcemia can lead to cardiac toxicity, and the use of Ergocalciferol in this context requires particular consideration.


Q: Is there information about Ergocalciferol use during pregnancy?

Regulatory documents classify the medicine as Pregnancy Category C. Use in excess of the normal daily recommended amount is generally avoided unless the prescribing professional determines that the potential benefits outweigh the potential hazards.


Q: Does the use of Ergocalciferol change for people with liver disease?

The liver performs the initial, essential modification step required to activate the medicine. Due to this metabolic dependency, official information indicates that patients with severe liver disease may have reduced efficacy.


Q: Does Ergocalciferol require activation by the kidneys or liver to work?

Yes, Ergocalciferol is a pro-drug that requires activation in the body. The final, active molecule is produced through a two-step process that involves an initial modification in the liver followed by the final activation step in the kidneys.


Q: Is Ergocalciferol safe for use by older adults?

Regulatory labeling notes that clinical studies did not include a sufficient number of geriatric patients (older adults) to definitively determine whether they respond differently compared to younger adults. Safety monitoring remains a primary consideration for all age groups.


Q: Is Ergocalciferol appropriate for people with kidney problems?

Official labeling contraindicates the medicine for use in patients with severe renal impairment due to its reliance on the kidneys for activation. For individuals with less severe kidney problems, its use requires particular caution and frequent medical monitoring.


Q: Can Ergocalciferol be used in children for Vitamin D deficiency?

Ergocalciferol is indicated for conditions resulting from deficiency, such as rickets, and can be used in pediatric patients. However, official information stresses that doses must be highly individualized and its use is strictly restricted in specific infant populations.


Q: How does the body eliminate Ergocalciferol and its breakdown products?

Official treatment for overdose involves processes to increase urinary calcium excretion, which indicates the renal system is involved in managing the minerals affected by the medicine.


Q: Does alcohol consumption affect how Ergocalciferol works?

Based on information from one authoritative medical source, it is currently unknown if drinking alcohol will affect how Ergocalciferol works in the body.


Q: What is the purpose of taking a high-strength Ergocalciferol product?

High-strength Ergocalciferol products (such as a 50,000 IU dose) are typically prescribed to rapidly address a severe deficiency or to manage certain chronic conditions like hypoparathyroidism, aiming to restore normal blood mineral levels.

How should Ergocalciferol be stored and disposed of?

How to Store and Dispose of Ergocalciferol

Storage Requirements

Ergocalciferol must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. The medicine must be explicitly protected from light and moisture to preserve its stability.

Regulatory documents mandate that the product be dispensed and stored in a tight, light-resistant container. Furthermore, as a critical safety measure, Ergocalciferol must be stored out of the reach of children.

Disposal Instructions

Unused or expired Ergocalciferol must be disposed of in accordance with local requirements; the medicine should not be discarded via wastewater or general household waste. Patients are instructed to consult their pharmacist or local authority for guidance on proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ergocalciferol found in:

A-Z Index: